Canine lymphoma patient Nettie receives her final treatment with TANOVEA-CA1 (Rabacfosadine for injection)
TANOVEA-CA1, the first lymphoma treatment for dogs conditionally approved by the FDA, is administered in five in-office visits by a team consisting of a veterinarian and trained assistants. The sessions take approximately 30 minutes and the dogs are generally not sedated. As with other cytotoxic drugs, the use of TANOVEA-CA1 follows strict safety protocols. This short video filmed by Dr. Sue Ettinger, a board certified veterinary oncologist, describes Nettie’s treatment including some of the procedures for safe handling of the medication.
Watch on Youtube: https://youtu.be/_ggzOJaDVvg